Department of Radiation Oncology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea , kongmoonkyoo@khu.ac.kr
Abstract: (849 Views)
Background:The optimal inter-fraction interval in fractionated thoracic radiosurgery remains unclear. Several institutions maintain at least a 48-hour interval between each radiosurgery fraction. However, evidence supporting such radiosurgery schedule is lacking. Since 2014, we have performed daily fractionated thoracic radiosurgery without interruption. In this study, we evaluated the safety of daily administration of fractionated thoracic radiosurgery in patients with primary or metastatic lung cancer. Materials and methods: Patients who received radical or salvage fractionated radiosurgery for treatment of primary or metastatic lung cancer were included in this study. All patients received fractionated radiosurgery divided into 2-4 fractions administered daily without interruption. Radiosurgery-induced toxicities were evaluated.Results:Eighty-eight patients and 94 lung masses were treated. Radiosurgery-induced leukopenia and grade 5 toxicity did not occur. One patient experienced radiosurgery-induced grade 4 pneumonitis and dyspnea. Grade 3 pneumonitis, dyspnea, and fatigue developed in 23 (24.5%), 2 (2.1%), and 2 (2.1%) patients, respectively. Four (4.3%) patients experienced rib fracture. Dyspnea, fatigue, nausea, and pneumonitis were more common and severe in patients with central lung lesions. In contrast, dermatitis and rib fracture developed only in patients with peripheral lung lesions.Conclusions: Daily fractionated radiosurgery is safe and well-tolerated in patients with primary or metastatic lung cancer. For patient convenience and better treatment outcomes, daily-fractionated thoracic radiosurgery can be considered.
1. 1. Blomgren H, Lax I, Naslund I, Svanstrom R (1995) Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol, 34(6): 861-70. [DOI:10.3109/02841869509127197] [PMID]
2. Uematsu M, Shioda A, Tahara K, Fukui T, Yamamoto F, Tsumatori G, et al. (1998) Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer, 82(6): 1062-70.
https://doi.org/10.1002/(SICI)1097-0142(19980315)82:6<1062::AID-CNCR8>3.0.CO;2-G [DOI:10.1002/(SICI)1097-0142(19980315)82:63.0.CO;2-G]
3. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA, 303(11): 1070-6. [DOI:10.1001/jama.2010.261] [PMID] []
4. Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, et al. (2012) Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys, 82(2): 967-73. [DOI:10.1016/j.ijrobp.2010.12.039] [PMID]
5. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol, 16(6): 630-7. [DOI:10.1016/S1470-2045(15)70168-3]
6. Videtic GM, Reddy CA, Sorenson L (2013) A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer. Support Care Cancer, 21(1): 211-8. [DOI:10.1007/s00520-012-1513-9] [PMID]
7. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, et al. (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys, 75(3): 677-82. [DOI:10.1016/j.ijrobp.2008.11.042] [PMID]
8. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol, 27(20): 3290-6. [DOI:10.1200/JCO.2008.21.5681] [PMID]
9. Videtic GM, Stephans K, Reddy C, Gajdos S, Kolar M, Clouser E, et al. (2010) Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. Int J Radiat Oncol Biol Phys, 77(2): 344-9. [DOI:10.1016/j.ijrobp.2009.05.004] [PMID]
10. Kong M, Sung JY, Lee SH (2020) Reactive oxygen species modulator 1 is Associated with Poor Survival in Patients with Non-Small Cell Lung Cancer After Stereotactic Fractionated Radiosurgery: A Retrospective Pilot Study. Onco Targets Ther, 13: 8173-80. [DOI:10.2147/OTT.S266344] [PMID] []
11. Kim MS, Kim W, Park IH, Kim HJ, Lee E, Jung JH, et al. (2015) Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery. Radiat Oncol J, 33(4): 265-75.
https://doi.org/10.1016/j.ijrobp.2015.07.1217 [DOI:10.3857/roj.2015.33.4.265]
12. Qiu B, Aili A, Xue L, Jiang P, Wang J (2020) Advances in radiobiology of stereotactic ablative radiotherapy. Front Oncol, 10: 1165. [DOI:10.3389/fonc.2020.01165] [PMID] []
13. Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys, 88(2): 254-62. [DOI:10.1016/j.ijrobp.2013.07.022] [PMID] []
14. Fowler JF, Welsh JS, Howard SP (2004) Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys, 59(1): 242-9. [DOI:10.1016/j.ijrobp.2004.01.004] [PMID]
15. Song CW, Griffin RJ, Lee YJ, Cho H, Seo J, Park I, et al. (2019) Reoxygenation and Repopulation of Tumor Cells after Ablative Hypofractionated Radiotherapy (SBRT and SRS) in Murine Tumors. Radiat Res, 192(2): 159-68. [DOI:10.1667/RR15346.1] [PMID]
16. Steel GG, McMillan TJ, Peacock JH (1989) The 5Rs of radiobiology. Int J Radiat Biol, 56(6): 1045-8. [DOI:10.1080/09553008914552491] [PMID]
17. Goldstein M and Kastan MB (2015) The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med, 66: 129-43. [DOI:10.1146/annurev-med-081313-121208] [PMID]
18. Hall EJ and Brenner DJ (1993) The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys, 25(2): 381-5. [DOI:10.1016/0360-3016(93)90367-5]
19. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, et al. (2001) Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys, 51(3): 666-70. [DOI:10.1016/S0360-3016(01)01703-5]
20. Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, et al. (2006) Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 66(1): 117-25. [DOI:10.1016/j.ijrobp.2006.04.013] [PMID]
21. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, et al. (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys, 76(2): 326-32. [DOI:10.1016/j.ijrobp.2009.09.042] [PMID]
22. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol, 24(30): 4833-9. [DOI:10.1200/JCO.2006.07.5937] [PMID]
23. Abel S, Hasan S, Horne ZD, Colonias A, Wegner RE (2019) Stereotactic body radiation therapy in early-stage NSCLC: historical review, contemporary evidence and future implications. Lung Cancer Manag, 8(1): LMT09. [DOI:10.2217/lmt-2018-0013] [PMID] []
24. Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, et al. (2015) LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol, 88(1051): 20150036. [DOI:10.1259/bjr.20150036] [PMID] []